CoChat

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Open access
Wu, Wenchao, Nelson, Geoffrey M., Koch, Raphael, Donovan, Katherine A., Nowak, Radosław P., Heavican-Foral, Tayla B., Nirmal, Ajit J., Liu, Huiyun, Yang, Lei, Duffy, Jessica, Powers, Foster, Stevenson, Kristen E., Jones, Marcus Kenneth, Ng, Samuel Y., Wu, Gongwei, Jain, Salvia, Xu, Ran, Amaka, Sam, Trevisani, Christopher, Donaldson, Nicholas L., Hagner, Patrick R., de Leval, Laurence, Gaulard, Philippe, Iqbal, Javeed, Thakurta, Anjan, Fischer, Eric S., Adelman, Karen, Weinstock, David M. · 2022 · Blood
Cited by 39

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Immunomodulatory (IMiD) agents like lenalidomide and pomalidomide induce the recruitment of IKZF1 and other targets to the CRL4CRBN E3 ubiquitin ligase, resulting in their ubiquitination and degradation. These agents are highly active in B-cell lymphomas and a subset of myeloid diseases but have compromised effects in T-cell lymphomas (TCLs). Here, we show that 2 factors determine resistance to IMiDs among TCLs. First, limited CRBN expression reduces IMiD activity in TCLs but can be overcome by newer-generation degrader CC-92480. Using mass spectrometry, we show that CC-92480 selectively degrades IKZF1 and ZFP91 in TCL cells with greater potency than pomalidomide. As a result, CC-92480 is highly active against multiple TCL subtypes and showed greater efficacy than pomalidomide across 4 in vivo TCL models. Second, we demonstrate that ZFP91 functions as a bona fide transcription factor that coregulates cell survival with IKZF1 in IMiD-resistant TCLs. By activating keynote genes from WNT, NF-kB, and MAP kinase signaling, ZFP91 directly promotes resistance to IKZF1 loss. Moreover, lenalidomide-sensitive TCLs can acquire stable resistance via ZFP91 rewiring, which involves casein kinase 2–mediated c-Jun inactivation. Overall, these findings identify a critical transcription factor network within TCLs and provide clinical proof of concept for the novel therapy using next-generation degraders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021014701

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 39

Metadata

Authors
Wu, W., Nelson, G. M., Koch, R., Donovan, K. A., Nowak, R. P., Heavican-Foral, T. B., Nirmal, A. J., Liu, H., Yang, L., Duffy, J., Powers, F., Stevenson, K. E., Jones, M. K., Ng, S. Y., Wu, G., Jain, S., Xu, R., Amaka, S., Trevisani, C., Donaldson, N. L., Hagner, P. R., de Leval, L., Gaulard, P., Iqbal, J., Thakurta, A., Fischer, E. S., Adelman, K., & Weinstock, D. M.
Venue
Blood
Published
2022-03-31
Volume
139
Issue
13
Pages
2024-2037
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4200613615
Cited by
39
References
12
FWCI
1.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. https://app.cochat.ai/papers/10.1182/blood.2021014701
The paper
Wu, W., Nelson, G. M., Koch, R., Donovan, K. A., Nowak, R. P., Heavican-Foral, T. B., Nirmal, A. J., Liu, H., Yang, L., Duffy, J., Powers, F., Stevenson, K. E., Jones, M. K., Ng, S. Y., Wu, G., Jain, S., Xu, R., Amaka, S., Trevisani, C., . . . Weinstock, D. M. (2022). Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood. https://doi.org/10.1182/blood.2021014701

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.